Equipment and Procedure Guide - BOTOX to Treat OAB and OAB-NC

Sep 27, 2026

Uploaded by Mabel

Equipment and procedure guide for administering BOTOX® to adults with overactive bladder (OAB) and overactive bladder due to a neurologic condition (OAB-NC). Provides indications, including treatment of urge urinary incontinence, urgency, and frequency in patients with inadequate response or intolerance to anticholinergics, and detrusor overactivity associated with neurologic conditions such as SCI and MS. Includes important safety information with boxed warnings on distant spread of toxin effects, contraindications related to infection and urinary conditions, ordering details with NDCs, storage duration, and flexible versus rigid cystoscopic injection needle options, along with ordering support via Allergan Direct®.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages9

Reading Time23 min

AccessFree to download

Indications

Adult bladder dysfunction: Overactive Bladder (OAB)

Detrusor overactivity associated with a neurologic condition

Important Safety Information

Boxed warning: Distant spread of toxin effect

Contraindications

Equipment for administering BOTOX

Flexible needle options

Rigid needle options

Ordering and storage guidance

National Drug Codes (NDCs)

Storage conditions

Equipment and procedure guide for administering BOTOX® to OAB* and OAB-NC† patients *Overactive bladder. †Overactive bladder due to a neurologic condition. INDICATIONS Adult Bladder Dysfunction Overactive Bladder BOTOX® (onabotulinumtoxinA) for injection is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency in adults who have an inadequate response to or are intolerant of an anticholinergic medication. Detrusor Overactivity Associated With a Neurologic Condition BOTOX is indicated for the treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition (eg, SCI, MS) in adults who have an inadequate response to or are intolerant of an anticholinergic medication. IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING WARNING: DISTANT SPREAD OF TOXIN EFFECT Postmarketing reports indicate that the effects of BOTOX and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening, and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have an underlying condition that would predispose them to these symptoms. In unapproved uses and approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and spasticity and at lower doses. Please see additional Important Safety Information throughout. Please see accompanying full Prescribing Information, including Boxed Warning and Medication Guide, or visit [https://www.rxabbvie.com/pdf/botox_pi.pdf](https://www.rxabbvie.com/pdf/botox_pi.pdf) Equipment for administering BOTOX® Flexible and rigid needle information Order what you want, when you want it, with Allergan Direct® Enrolling in Allergan Direct® provides you with online convenience, so you can manage your account, purchase products, pay your AbbVie® bills, and access valuable account reports around your schedule. Set up an account with Allergan Direct® today by calling AbbVie® customer service at 1-855-246-3728. Once your account is established, you can order BOTOX® and other products through Allergan Direct® at: [AllerganDirect.com](AllerganDirect.com). IMPORTANT SAFETY INFORMATION (continued) CONTRAINDICATIONS BOTOX is contraindicated in the presence of infection at the proposed injection site(s) and in patients who are hypersensitive to any botulinum toxin product or to any of the components in the formulation. BOTOX is contraindicated for intradetrusor injection inpatients with a urinary tract infection (UTI), or in patients with urinary retention or post-void residual (PVR) urine volume >200 mL who are not routinely performing clean intermittent self-catheterization (CIC). Ordering BOTOX® When ordering BOTOX® by phone or online, please use the following National Drug Codes (NDCs): BOTOX® 100-Unit vial: NDC 0023-1145-01 BOTOX® 200-Unit vial: NDC 0023-3921-02 WARNINGS AND PRECAUTIONS Spread of Toxin Effect See Boxed Warning. Lack of Interchangeability Between Botulinum Toxin Products The potency Units of BOTOX are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, Units of biological activity of BOTOX cannot be compared to nor converted into Units of anyother botulinum toxin products assessed with any other specific assay method. Please see additional Important Safety Information t

FAQs

What conditions are covered by BOTOX for adults with OAB and OAB-NC?

BOTOX is indicated for overactive bladder symptoms such as urge urinary incontinence, urgency, and frequency when patients have inadequate response to or intolerance of an anticholinergic medication. It is also indicated for urinary incontinence due to detrusor overactivity associated with neurologic conditions (e.g., SCI, MS) under similar anticholinergic response/tolerability criteria.

What is the boxed warning about with BOTOX?

The boxed warning addresses distant spread of toxin effect, where postmarketing reports describe symptoms consistent with botulinum toxin effects spreading from the injection area. These effects can include weakness, swallowing and breathing difficulties, and life-threatening events.

What are key contraindications for BOTOX administration?

BOTOX is contraindicated when there is infection at the proposed injection site(s) or hypersensitivity to botulinum toxin products/components. It is also contraindicated for intradetrusor injection in patients with urinary tract infection, or urinary retention/post-void residual urine volume >200 mL who are not routinely performing clean intermittent self-catheterization.

Sep 27, 2026

Uploaded by Mabel